SCHEMBL14033733

SCHEMBL14033733

OC(c1ccc(Cl)cc1)c1ccc2ccccc2c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UGT2B7 P16662 1/20 0.55
CYP2A6 P11509 1/20 0.54
HTR1A P08908 1/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
ATM Q13315 1/20 0.47
SLC6A2 P23975 8/20 0.44
SLC6A4 P31645 8/20 0.44
SLC6A3 Q01959 8/20 0.44
KCNH2 Q12809 4/20 0.44
CYP2D6 P10635 3/20 0.44
CYP3A4 P08684 2/20 0.44
AOC3 Q16853 1/20 0.44
CYP1A2 P05177 1/20 0.44
TSHR P16473 1/20 0.44
HIF1A Q16665 1/20 0.44
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CHEK2 O96017 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30033673 0.88 UGT2B7 (0.68) UGT2B7MEN1KMT2AATMSLC6A2
SCHEMBL600527 0.88 UGT2B7 (0.68) UGT2B7MEN1KMT2AATMSLC6A2
SCHEMBL477557 0.86 UGT2B7 (0.61) UGT2B7MEN1KMT2AATMSLC6A2
SCHEMBL477559 0.86 UGT2B7 (0.61) UGT2B7MEN1KMT2AATMSLC6A2
SCHEMBL30161628 0.86 UGT2B7 (0.61) UGT2B7MEN1KMT2AATMSLC6A2
SCHEMBL26326669 0.81 UGT2B7 (0.55) UGT2B7MEN1KMT2AATMSLC6A2
SCHEMBL26326654 0.81 UGT2B7 (0.60) UGT2B7CYP2A6MEN1KMT2AATM
SCHEMBL26326655 0.81 UGT2B7 (0.55) UGT2B7CYP2A6MEN1KMT2AATM
SCHEMBL12405817 0.80 UGT2B7 (0.53) UGT2B7MEN1KMT2AATMSLC6A2
SCHEMBL477379 0.79 IDO1 (0.54) HTR1AMEN1KMT2ASLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432268-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2008-10-07 US disclosed
US-7432268-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2008-10-07 US disclosed